These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy. Bardia A; Pusztai L; Albain K; Ciruelos EM; Im SA; Hershman D; Kalinsky K; Isaacs C; Loirat D; Testa L; Tokunaga E; Wu J; Dry H; Barlow W; Kozarski R; Maxwell M; Harbeck N; Sharma P Ther Adv Med Oncol; 2024; 16():17588359241248336. PubMed ID: 38686016 [TBL] [Abstract][Full Text] [Related]
4. Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study. Bardia A; Krop IE; Kogawa T; Juric D; Tolcher AW; Hamilton EP; Mukohara T; Lisberg A; Shimizu T; Spira AI; Tsurutani J; Damodaran S; Papadopoulos KP; Greenberg J; Kobayashi F; Zebger-Gong H; Wong R; Kawasaki Y; Nakamura T; Meric-Bernstam F J Clin Oncol; 2024 Jul; 42(19):2281-2294. PubMed ID: 38652877 [TBL] [Abstract][Full Text] [Related]
5. TROPION-Lung08: phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC. Levy BP; Felip E; Reck M; Yang JC; Cappuzzo F; Yoneshima Y; Zhou C; Rawat S; Xie J; Basak P; Xu L; Sands J Future Oncol; 2023 Jul; 19(21):1461-1472. PubMed ID: 37249038 [TBL] [Abstract][Full Text] [Related]
6. Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan. Heist RS; Sands J; Bardia A; Shimizu T; Lisberg A; Krop I; Yamamoto N; Kogawa T; Al-Hashimi S; Fung SSM; Galor A; Pisetzky F; Basak P; Lau C; Meric-Bernstam F Cancer Treat Rev; 2024 Apr; 125():102720. PubMed ID: 38502995 [TBL] [Abstract][Full Text] [Related]
7. Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells. Okajima D; Yasuda S; Maejima T; Karibe T; Sakurai K; Aida T; Toki T; Yamaguchi J; Kitamura M; Kamei R; Fujitani T; Honda T; Shibutani T; Muramatsu S; Nakada T; Goto R; Takahashi S; Yamaguchi M; Hamada H; Noguchi Y; Murakami M; Abe Y; Agatsuma T Mol Cancer Ther; 2021 Dec; 20(12):2329-2340. PubMed ID: 34413126 [TBL] [Abstract][Full Text] [Related]
8. Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer. Shastry M; Jacob S; Rugo HS; Hamilton E Breast; 2022 Dec; 66():169-177. PubMed ID: 36302269 [TBL] [Abstract][Full Text] [Related]
11. Trastuzumab deruxtecan in previously treated HER2-positive metastatic breast cancer: Plain language summary of the DESTINY-Breast01 study. Modi S Future Oncol; 2021 Sep; 17(26):3415-3423. PubMed ID: 34263665 [TBL] [Abstract][Full Text] [Related]
12. Exposure-Response Relationships in Patients With HER2-Positive Metastatic Breast Cancer and Other Solid Tumors Treated With Trastuzumab Deruxtecan. Yin O; Iwata H; Lin CC; Tamura K; Watanabe J; Wada R; Kastrissios H; AbuTarif M; Garimella T; Lee C; Zhang L; Shahidi J; LaCreta F Clin Pharmacol Ther; 2021 Oct; 110(4):986-996. PubMed ID: 33999422 [TBL] [Abstract][Full Text] [Related]
13. Safety evaluation of Datopotamab deruxtecan for triple-negative breast cancer: a meta-analysis. Gadaleta-Caldarola G; Lanotte L; Infusino S; Gadaleta-Caldarola A; Schipilliti FM; Citrigno C; Petrarota C; Cusmai A; Rizzo A Cancer Treat Res Commun; 2023; 37():100775. PubMed ID: 37956525 [TBL] [Abstract][Full Text] [Related]
14. Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody-drug conjugates in the breast cancer treatment landscape. Adams E; Wildiers H; Neven P; Punie K ESMO Open; 2021 Aug; 6(4):100204. PubMed ID: 34225076 [TBL] [Abstract][Full Text] [Related]
15. Datopotamab deruxtecan: A novel antibody drug conjugate for triple-negative breast cancer. Schipilliti FM; Drittone D; Mazzuca F; La Forgia D; Guven DC; Rizzo A Heliyon; 2024 Apr; 10(7):e28385. PubMed ID: 38560142 [TBL] [Abstract][Full Text] [Related]
16. Trastuzumab deruxtecan for HER2+ advanced breast cancer. Lee J; Park YH Future Oncol; 2022 Jan; 18(1):7-19. PubMed ID: 34823373 [TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a phase II study protocol (SHAMROCK study). Dowling GP; Toomey S; Bredin P; Parker I; Mulroe E; Marron J; McLoughlin O; Teiserskiene A; Power C; O'Shea AM; Greally M; Morris PG; Duke D; Hill ADK; Hennessy BT BMC Cancer; 2024 Jan; 24(1):91. PubMed ID: 38233810 [TBL] [Abstract][Full Text] [Related]
18. The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan. Schreiber AR; O'Bryant CL; Kabos P; Diamond JR Expert Rev Anticancer Ther; 2023; 23(10):1061-1069. PubMed ID: 37742278 [TBL] [Abstract][Full Text] [Related]
19. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. Doi T; Shitara K; Naito Y; Shimomura A; Fujiwara Y; Yonemori K; Shimizu C; Shimoi T; Kuboki Y; Matsubara N; Kitano A; Jikoh T; Lee C; Fujisaki Y; Ogitani Y; Yver A; Tamura K Lancet Oncol; 2017 Nov; 18(11):1512-1522. PubMed ID: 29037983 [TBL] [Abstract][Full Text] [Related]